Timothy Burns, MD, PhD: Emerging Trials in First-Line KRAS-Mutant NSCLC – SUNRAY-01

Dr. Burns discusses the recent advances in targeting KRAS mutations in patients with NSCLC. He describes the SUNRAY-01 trial, which is investigating the use of olomorasib plus pembrolizumab with or without chemotherapy vs standard of care in the first-line treatment of KRAS G12C-mutant NSCLC.

Topics covered:

• The rationale for investigating olomorasib combination therapy in KRAS G12C-mutant NSCLC
• Trial design of the phase 3 SUNRAY-01 trial
• Key study features, such as allowing KRAS tumors of any PD-L1 status

NSCLC=non-small cell lung cancer; PD-L1=programmed death-ligand 1